@article{7277cbb7c76a4ddba17b9a3e61b5bcf4,
title = "Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial",
abstract = "Platinum-based doublets are the cornerstone of treatment in advanced non-small-cell lung cancer (NSCLC) and often include vinorelbine or taxanes. A predictive biomarker is greatly needed to select chemotherapy-sensitive patients for these microtubule-interfering agents. Class III β-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role of TUBB3 in advanced NSCLC.",
keywords = "Adenocarcinoma, Adolescent, Adult, Aged, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Disease-Free Survival, Female, Humans, Lung Neoplasms, Male, Middle Aged, Paclitaxel, Prognosis, Survival Rate, Treatment Outcome, Tubulin, Tumor Markers, Biological, Vinblastine",
author = "Vilmar, {Adam Christian} and Eric Santoni-Rugiu and S{\o}rensen, {Jens Benn}",
note = "{\textcopyright}2011 AACR.",
year = "2011",
doi = "10.1158/1078-0432.CCR-11-0658",
language = "English",
volume = "17",
pages = "5205--14",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "15",
}